Source comparison
Does PT-141 Support Sexual Function Research? Comparison
Mechanism MC4R agonist. Activates hypothalamic desire pathways PDE5 inhibitor. Increases genital blood flow Serotonin modulator. Alters neurotransmitter balance PT-141 is the only compound that directly targets central sexual motivation circuits Onset Time 30–
This comparison does not assign a generated winner or score.
- Mechanism
- MC4R agonist. Activates hypothalamic desire pathways
- PDE5 inhibitor. Increases genital blood flow
- Serotonin modulator. Alters neurotransmitter balance
- PT-141 is the only compound that directly targets central sexual motivation circuits
- Onset Time
- 30–60 minutes post-injection
- 30–60 minutes oral
- Requires daily dosing for 4–8 weeks to show effect
- PT-141 works on-demand, making it more suitable for acute desire studies
- Administration
- Subcutaneous injection, as-needed dosing
- Oral tablet, as-needed dosing
- Daily oral tablet, chronic administration required
- PT-141 requires injection training but offers precise dose control
- Primary Population
- Premenopausal women with HSDD
- Men and women with arousal/blood flow deficits
- PT-141 and flibanserin target overlapping populations but through different pathways
- Adverse Events
- Nausea (40%), flushing (13%), headache (11%)
- Headache (16%), flushing (10%), nasal congestion (4%)
- Dizziness (11%), somnolence (11%), nausea (10%)
- PT-141's nausea rate is highest but transient; flibanserin's CNS effects are persistent